Eli Lilly LLY Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Revenue by Product | ||||||
| Jardiance | $3.53B+2.9% | $3.43B-11.1% | $3.86B+7.6% | $3.59B-2.2% | $3.67B+9.8% | |
| Mounjaro | $27.79B+21.0% | $22.97B+20.3% | $19.09B+21.7% | $15.68B+15.5% | $13.58B+17.6% | |
| Neuroscience | $1.5B+7.9% | $1.39B+4.9% | $1.33B-2.7% | $1.36B+0.3% | $1.36B-7.9% | |
| Other cardiometabolic health | $3.97B-1.0% | $4.01B-4.8% | $4.21B+0.4% | $4.19B-4.2% | $4.38B-1.8% | |
| Other immunology | $1.83B+8.6% | $1.68B+9.8% | $1.53B+11.2% | $1.38B+12.2% | $1.23B+8.5% | |
| Other oncology | $3.83B+4.8% | $3.65B+0.2% | $3.65B+2.1% | $3.57B+2.8% | $3.48B+0.9% | |
| Taltz | $3.53B-0.8% | $3.56B+2.9% | $3.46B+0.6% | $3.44B+0.7% | $3.42B+4.8% | |
| Trulicity | $4.1B-4.1% | $4.28B-4.8% | $4.49B-5.3% | $4.74B-3.1% | $4.89B-6.9% | |
| Verzenio | $5.87B+2.5% | $5.72B+0.9% | $5.67B+1.8% | $5.57B+2.9% | $5.42B+2.0% | |
| Zepbound | $15.39B+13.6% | $13.54B+21.0% | $11.19B+26.3% | $8.86B+31.8% | $6.72B+36.4% | |
| Potential achievements by Product | ||||||
| Ebglyss | $4.9B-1.0% | $4.95B-1.0% | $5B0.0% | $5B0.0% | $5B0.0% | |
| R&D by Product | ||||||
| Early-stage | $5.16B+5.7% | $4.88B+9.9% | $4.44B+6.1% | $4.19B+3.2% | $4.06B+3.5% | |
| Late-stage | $8.96B+5.9% | $8.46B+4.2% | $8.12B+6.2% | $7.64B+6.9% | $7.15B+1.0% | |
| Revenue by Geography | ||||||
| China | $2.19B+12.4% | $1.95B+2.3% | $1.91B+5.6% | $1.81B+4.1% | $1.73B+4.5% | |
| Europe | $12.82B+10.9% | $11.56B+5.9% | $10.91B+20.7% | $9.04B+14.9% | $7.87B+13.7% | |
| Japan | $2.3B+7.9% | $2.13B+4.7% | $2.04B+6.6% | $1.91B+3.1% | $1.85B+2.1% | |
| Outside U.S. | $25.14B+15.9% | $21.7B+9.7% | $19.78B+15.6% | $17.11B+8.1% | $15.83B+7.9% | |
| Rest of world | $7.83B+29.3% | $6.06B+22.8% | $4.93B+13.3% | $4.35B-0.5% | $4.38B+2.4% | |
| U.S. | $47.11B+8.3% | $43.48B+9.7% | $39.64B+9.6% | $36.15B+9.0% | $33.17B+9.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Eli Lilly break its business down?
- Eli Lilly (LLY) reports revenue by product across 10 parts — Jardiance, Mounjaro, Neuroscience, Other cardiometabolic health and Other immunology. Each is extracted from the segment footnotes and tracked over time.
- Where does Eli Lilly's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Eli Lilly's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
